CHANGE MY LOCATION
Business and Finance
Business News
McCain, Obama trade barbs in town hall debate- John McCain dismissively called rival Barack Obama "that one," Obama mocked McCain's "Straight Talk Express," and both left the debate stage to return to the campaign trail Wednesday.
Analysis: Obama gains, McCain seeks game-changer- Barack Obama made strides toward easing voters' concerns about his candidacy in Tuesday night's debate. John McCain, despite raising pointed questions about his rival's readiness, didn't create the game-changing moment he'll need between now and Election Day.
Asian stocks plunge on unabated credit market woes- Asian stock markets tumbled Wednesday, with Japan's Nikkei index sinking nearly 10 percent, as recent steps by the world's major economies to fortify credit markets failed to stem fears that the spreading financial crisis could spawn a global recession.
- With financial markets still tumbling, the Federal Reserve is signaling that it might cut interest rates after a series of bold steps by federal regulators failed to stem the slide. Neither presidential candidate offered a solution.
- U.S. and Japanese researchers are among the favorites to win the Nobel Prize in chemistry, but don't expect any recent discoveries to get the nod.
- A U.S. military officer warned Pentagon officials that an American detainee was being driven nearly insane by months of punishing isolation and sensory deprivation in a U.S. military brig, according to documents obtained by The Associated Press.
- Hurricane Norbert strengthened into a powerful Category 2 storm over the Pacific Ocean and forecasters warned that it could reach Mexico's Baja California peninsula by the weekend.
Travis Barker thankful to be alive after jet crash- Former Blink-182 drummer Travis Barker, who always has been afraid of flying, says he's glad to be alive after suffering severe burns in a fiery plane crash last month.
Bosox-Rays renew rivalry, Manny in middle of NLCS- Exactly why the Boston Red Sox and Tampa Bay Rays tangle so much is hard to tell. Blame it on a high-and-tight pitch here, a hard slide there. Whatever, this much is true: The teams playing in the AL championship series sure get into a lot of scraps. "There's no hatred," injured Red Sox pitcher Curt Schilling insisted Tuesday in an e-mail to The Associated Press.
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
SAN DIEGO
(Map)
-
"We are excited to share emerging data on the therapeutic potential of
BSI-201 as a novel oncology platform drug, in the area of DNA repair
inhibition," said
The data presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting today, evaluated BSI-201 as both a single agent and in combination with topotecan in human OVCAR-3 xenografts resistant to adriamycin, melphalan and cisplatin. Administered as monotherapy, BSI-201 demonstrated significant tumor growth delay and improved survival. In combination with topotecan, BSI-201 significantly inhibited tumor growth and increased the percentage of complete tumor regressions, compared with topotecan alone.
Based on the preclinical findings and positive Phase 1 results, BiPar is currently enrolling in a clinical trial of BSI-201 in combination with topotecan in advanced ovarian cancer and will soon launch a Phase 2 monotherapy trial in BRCA-negative ovarian cancer patients. These ovarian cancer trials represent an important expansion of BiPar's on-going Phase 2 programs in breast and brain cancer patients.
About BSI-201
BSI-201, a novel DNA repair inhibitor of PARP, is BiPar's lead product candidate. BSI-201 is a small molecule candidate with the potential of becoming a superior, new class of treatment that possesses in-vivo activity across a broad range of tumor types, both as monotherapy and in combination with standard-of-care chemotherapy regimens. In addition, Phase 1 studies of BSI-201 have demonstrated that the drug is well-tolerated with minimal adverse side effects. BSI-201 is currently in Phase 2 clinical trials in multiple solid tumor settings, including breast, ovarian, brain and uterine cancers.
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus on novel mechanisms of action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BiPar has successfully advanced BSI-201 from an IND to a broad Phase 2 solid tumor clinical program in less than two years.
|
|
More Business_and_Finance Releases
(RIMM): BlackBerry Takes the World by Storm with Verizon Wireless and Vodafone
(VZ): Verizon and i-SAFE Partner for Second Cyber Safety Week in Colorado
